Ibuprofen Would Be the First-Line Nonsteroidal Anti-inflammatory Drug for Polymyalgia Rheumatica: A Case Series of Five Patients

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 May 24

PMID 38784367

Authors

Shigeko Inokuma

Taro Okazaki

Hiroki Morishita

Masanori Tsuji

Yoshimasa Goto

Affiliations

Soon will be listed here.

Abstract

The primary treatment of choice for polymyalgia rheumatica (PMR) is corticosteroids, which are better avoided for elderly patients susceptible to PMR. The cases of five patients cured with only a small dosage of 600 mg/day ibuprofen without steroids or methotrexate are reported. Their clinical features were compared with those of the 26 PMR patients who had steroids and/or methotrexate in addition to ibuprofen. PMR was diagnosed based on the 2015 EULAR/ACR criteria. They were all females aged 73-80. They all had no giant cell arteritis or autoantibodies. Nonsteroidal anti-inflammatory drugs (NSAIDs) other than ibuprofen had not worked in four cases; for the one, ibuprofen was the first NSAID. Their serum CRP levels were 1.57-12.8 mg/dL at ibuprofen introduction. Colchicine was co-administered in two patients. At the next visit three to seven days after ibuprofen introduction, they all showed a clear recovery with a CRP level decrease. Ibuprofen tapering was started within three months, and no relapse was until two to five years' follow-up. Comparison with the 26 patients who had additional steroid and/or methotrexate showed that the disease duration until ibuprofen introduction was statistically significantly shorter in the five patients (1.40±0.65 vs 3.28±2.98 months). Ibuprofen would be the first-line drug for PMR, and its earliest use would be beneficial.

References

Crowson C, Matteson E . Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017; 47(2):253-256. PMC: 5623160. DOI: 10.1016/j.semarthrit.2017.04.001. View

Floris A, Piga M, Chessa E, Congia M, Erre G, Angioni M . Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2021; 41(1):19-31. PMC: 8724087. DOI: 10.1007/s10067-021-05819-z. View

Abu Esba L, Alqahtani R, Thomas A, Shamas N, Alswaidan L, Mardawi G . Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study. Infect Dis Ther. 2020; 10(1):253-268. PMC: 7604230. DOI: 10.1007/s40121-020-00363-w. View

Spiera R, Unizony S, Warrington K, Sloane J, Giannelou A, Nivens M . Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023; 389(14):1263-1272. DOI: 10.1056/NEJMoa2303452. View

Dasgupta B, Cimmino M, Maradit-Kremers H, Schmidt W, Schirmer M, Salvarani C . 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012; 71(4):484-92. PMC: 3298664. DOI: 10.1136/annrheumdis-2011-200329. View

Shah P, Marshall-Batty K, Smolen J, Tagaev J, Chen Q, Rodesney C . Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens. Antimicrob Agents Chemother. 2018; 62(3). PMC: 5826130. DOI: 10.1128/AAC.01574-17. View

Mackie S, Koduri G, Hill C, Wakefield R, Hutchings A, Loy C . Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open. 2015; 1(1):e000100. PMC: 4623371. DOI: 10.1136/rmdopen-2015-000100. View

Pennock N, Martinson H, Guo Q, Betts C, Jindal S, Tsujikawa T . Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer. 2018; 6(1):98. PMC: 6167844. DOI: 10.1186/s40425-018-0406-y. View

Colombo M, Wetzel A, Haumann H, Dally S, Kirtschig G, Joos S . Polymyalgia Rheumatica. Dtsch Arztebl Int. 2022; 119(24):411-417. PMC: 9533703. DOI: 10.3238/arztebl.m2022.0218. View

10.

Bombardo M, Malagola E, Chen R, Rudnicka A, Graf R, Sonda S . Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. Br J Pharmacol. 2017; 175(2):335-347. PMC: 5758389. DOI: 10.1111/bph.13867. View

11.

Bird H, Esselinckx W, DIXON A, Mowat A, WOOD P . An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979; 38(5):434-9. PMC: 1000388. DOI: 10.1136/ard.38.5.434. View

12.

Desgranges F, Tebib N, Lamy O, Kritikos A . Meningitis due to non-steroidal anti-inflammatory drugs: an often-overlooked complication of a widely used medication. BMJ Case Rep. 2019; 12(11). PMC: 6855853. DOI: 10.1136/bcr-2019-231619. View

13.

Manzo C . Incidence and Prevalence of Polymyalgia Rheumatica (PMR): The Importance of the Epidemiological Context. . Med Sci (Basel). 2019; 7(9). PMC: 6780278. DOI: 10.3390/medsci7090092. View

14.

Raleigh M, Stoddard J, Darrow H . Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. Am Fam Physician. 2022; 106(4):420-426. View

15.

Partington R, Muller S, Helliwell T, Mallen C, Abdul Sultan A . Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis. 2018; 77(12):1750-1756. DOI: 10.1136/annrheumdis-2018-213883. View

16.

Brown K, Collins A . Action of nonsteroidal, anti-inflammatory drugs on human and rat peripheral leucocyte migration in vitro. Ann Rheum Dis. 1977; 36(3):239-43. PMC: 1006672. DOI: 10.1136/ard.36.3.239. View